Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective Analysis
Kidney360 · 2026
DOI: 10.34067/kid.0000001107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, 2026. Verfasst von Benjamin Teruel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. Hauptthemen laut MEDLINE: Melphalan, Multiple Myeloma, Glomerular Filtration Rate, Hematopoietic Stem Cell Transplantation. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, DCI.
Abstract (Originalsprache)
Background
Accurate renal dosing of high dose melphalan as conditioning chemotherapy is critical for patients with multiple myeloma undergoing autologous stem cell transplant (ASCT). In clinical practice, serum creatinine (sCr) is used to eGFR for dosing calculations. The objective of our study was to compare sCr based eGFR to serum cystatin C based eGFR for melphalan dosing in patients undergoing ASCT for multiple myeloma to determine discrepancies in dosing and the effect on patient centered outcomes including chemotherapy-related toxicity, hospitalization and to assess IMWG response criteria at 3 and 12 months.
Methods
We conducted a retrospective study including 76 patients with multiple myeloma who received melphalan conditioning before ASCT. Melphalan dosing in all patients was based on pre-transplant eGFR calculated from sCr (200 mg/m2 for eGFR >50 mL/min, 140 mg/m 2 for eGFR < 50 mL/min). We calculated eGFR using both sCr and cystatin C levels prior to transplantation and observed the 30-day hospitalization from symptoms of melphalan toxicity. We identified a discordant patient group, whose cystatin C eGFR was calculated less than 50 mL/min compared to sCr eGFR >50 mL/min and would have qualified for a reduced melphalan dose.
Results
Of 76 patients, 13 (17%) were identified as having received a higher than intended dose of melphalan when eGFR was estimated using sCr rather than cystatin C (200 mg/m2 rather than 140 mg/m2, “discordant dosing”). 100% of discordant patients were hospitalized within 30 days of melphalan dosing compared to 60% of the concordant patients whose eGFR was greater than 50 mL/min with both cystatin C and sCr based eGFR, with melphalan dosing 200 mg/m2 (p = 0.006). Furthermore, patients with discordant dosing had a significantly longer hospitalization duration of 7days compared to 2.5 days in patients with concordant dosing (p=0.0014). More patients qualified for dose reduction using cystatin C based eGFR compared to combined sCr-cystatin C based eGFR (p=0.02).
Conclusions
Discordance between creatinine- and cystatin C-based eGFR calculations in ASCT patients was linked to inconsistent melphalan dosing and associated with an increase in adverse outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
- Myeloma & Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- University College Dublin School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
- School of Medicine, Department of Clinical Pharmacy and Outcome Sciences, Medical University of South Carolina, Charleston, SC, USA.
- Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA.
ORCID-Profile: Benjamin Teruel, Ashley L Golbus, Elaine Park, Patrick T Murray, James Davis, Blaithin A McMahon
Förderung
- NCI NIH HHS
- DCI
Zitieren
APA
Teruel, B., Golbus, A. L., Park, E., Hashmi, H., Murray, P. T., Davis, J., & McMahon, B. A. (2026). Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective Analysis. Kidney360. https://doi.org/10.34067/kid.0000001107
Vancouver
Teruel B, Golbus AL, Park E, Hashmi H, Murray PT, Davis J, et al. Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective Analysis. Kidney360. 2026. doi:10.34067/kid.0000001107
BibTeX
@article{Teruel2026,
author = {Teruel, Benjamin and Golbus, Ashley L and Park, Elaine and Hashmi, Hamza and Murray, Patrick T and Davis, James and McMahon, Blaithin A},
title = {Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective Analysis},
journal = {Kidney360},
year = {2026},
doi = {10.34067/kid.0000001107}
}
EUVIMED